Cargando…

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial

OBJECTIVES: To evaluate the 2-year clinical effectiveness of two gradual tapering strategies. The first strategy consisted of tapering the conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) first (i.e., methotrexate in ~90%), followed by the tumour necrosis factor inhibitor (TNF...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Mulligen, Elise, Weel, Angelique E, Hazes, J M, van der Helm-van Mil, Annette, de Jong, Pascal Hendrik Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatoid Arthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7456559/ https://www.ncbi.nlm.nih.gov/pubmed/32482645 http://dx.doi.org/10.1136/annrheumdis-2020-217485

Ejemplares similares

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial
por: van Mulligen, Elise, et al.
Publicado: (2020)

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
por: Verstappen, M, et al.
Publicado: (2020)

Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors
por: Terslev, L, et al.
Publicado: (2022)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Joint involvement in RA starts predominantly in the hands: functional, clinical and imaging studies in clinically suspect arthralgia and during progression to RA
por: Khidir, Sarah J H, et al.
Publicado: (2023)

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients
por: Humby, Frances, et al.
Publicado: (2019)

Is Anti–Citrullinated Protein Antibody–Positive Rheumatoid Arthritis Still a More Severe Disease Than Anti–Citrullinated Protein Antibody–Negative Rheumatoid Arthritis? A Longitudinal Cohort Study in Rheumatoid Arthritis Patients Diagnosed From 2000 Onward
por: Boer, Aleid C., et al.
Publicado: (2018)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art
por: Boeters, Debbie M, et al.
Publicado: (2017)

Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis
por: Riley, Thomas R, et al.
Publicado: (2021)

Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study
por: van Steenbergen, Hanna W, et al.
Publicado: (2015)

Validity of the rheumatoid arthritis MRI score applied to the forefeet using the OMERACT filter: a systematic literature review
por: Dakkak, Yousra J, et al.
Publicado: (2018)

Response to: ‘TARA Study: a new perspective on tapering drugs in RA’ by Mishra et al
por: van Mulligen, Elise, et al.
Publicado: (2020)

Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study
por: Emery, Paul, et al.
Publicado: (2020)

Hand function is already reduced before RA development and reflects subclinical tenosynovitis
por: Krijbolder, Doortje Isabelle, et al.
Publicado: (2023)

Evaluation of the joint distribution at disease presentation of patients with rheumatoid arthritis: a large study across continents
por: Bergstra, Sytske Anne, et al.
Publicado: (2017)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Intermetatarsal Bursitis, a Novel Feature of Juxtaarticular Inflammation in Early Rheumatoid Arthritis Related to Clinical Signs: Results of a Longitudinal Magnetic Resonance Imaging Study
por: van Dijk, Bastiaan T., et al.
Publicado: (2022)

What causes a small increase in radiographic progression in rheumatoid arthritis patients tapering TNF inhibitors?
por: Bouman, Chantal A M, et al.
Publicado: (2017)

Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial
por: Lillegraven, Siri, et al.
Publicado: (2023)

The Role of Genetics in Clinically Suspect Arthralgia and Rheumatoid Arthritis Development: A Large Cross‐Sectional Study
por: Maurits, Marc P., et al.
Publicado: (2022)

Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis
por: Scott, I C, et al.
Publicado: (2016)

Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis
por: Sharma, Chanakya, et al.
Publicado: (2020)

What is the prevalence of MRI-detected inflammation and erosions in small joints in the general population? A collation and analysis of published data
por: Mangnus, Lukas, et al.
Publicado: (2015)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

To treat or not to treat? Current attitudes on treatment aimed at modifying the disease burden in clinically suspect arthralgia: a survey among participants of the TREAT EARLIER trial and healthcare professionals
por: Krijbolder, Doortje I, et al.
Publicado: (2023)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment
por: Krijbolder, Doortje I, et al.
Publicado: (2023)

Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Nathalie, Luurssen-Masurel, et al.
Publicado: (2021)

The value of MRI for detecting subclinical joint inflammation in clinically suspect arthralgia
por: Boeren, Anna M. P., et al.
Publicado: (2022)

Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
por: Saleem, Benazir, et al.
Publicado: (2022)

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Moderate use of alcohol is associated with lower levels of C reactive protein but not with less severe joint inflammation: a cross-sectional study in early RA and healthy volunteers
por: Mangnus, Lukas, et al.
Publicado: (2018)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

Positive impact on 10-year outcome of the window of opportunity for conventional synthetic DMARDs in rheumatoid arthritis: results from the ESPOIR cohort
por: Kedra, Joanna, et al.
Publicado: (2022)

Patient and physician assessment in difficult-to-treat rheumatoid arthritis: patterns of subjective perception at early stages of b/tsDMARD treatment
por: Novella -Navarro, Marta, et al.
Publicado: (2023)

Correction to: Comparing cost-utility of DMARDs in autoantibody-negative rheumatoid arthritis patients
por: Luurssen-Masurel, Nathalie, et al.
Publicado: (2022)

Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
por: Curtis, Jeffrey R, et al.
Publicado: (2012)

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis
por: Tweehuysen, Lieke, et al.
Publicado: (2018)

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis
por: Yuan, Haoming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ki3k5ujk5o9kqhb5vn31dpi57f